Chengdu, China, October 14, 2021
Anticancer Bioscience Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31M to Advance Synthetic Lethality Approaches to Cancer Therapy
Chengdu, China, October 14, 2021 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that it had secured an additional CNY 68.4 million (~USD 10.6 million) from new Chinese investors. The seed extension financing was led by Three Rivers Capital, who joins existing private Chinese investors. The total raised in the seed round is now over USD31 million (around CNY 200 million).
The proceeds will be mainly used to accelerate the preclinical development of the company’s two most advanced programs, MYC-synthetic lethal and contact inhibition restoration. The funds will also be used to optimize lead compounds for polyploidy-synthetic lethal therapy and to identify additional lead compounds for the company’s contact inhibition restoration approach to combatting cancer.
ACB is applying synthetic lethal approaches to develop targeted cancer therapies. These have the potential to be much safer and more effective than current therapies. ACB has access to world-leading cancer biology expertise and drug discovery platforms that enable the company to identify novel compounds that can target both genetic and epigenetic vulnerabilities of cancer cells. ACB has bespoke chemical compound libraries and has invested in developing one of the world’s largest natural product libraries, providing a rich screening resource for potential cancer therapeutics.
Commenting on the financing, Dun Yang Ph.D., Founder, President, and CEO of ACB said, “This successful financing round is a further strong endorsement of our innovative approach to identifying first-in-class and best-in-class therapeutics for the treatment of cancer, using synthetic lethal strategies. It underlines our progress over the past months and will help accelerate our five drug discovery programs through optimization to candidate selection and IND enabling studies. We aim to initiate two clinical trials in 2022.”
Xiaoyin Chen, Investment Director at Three Rivers Capital said: “ACB is an emerging innovative biotech with global competitiveness. We firmly believe that only revolutionary innovations in drug discovery and development can generate great clinical benefits and value. ACB utilizes its unique small molecule libraries and screening approaches, combined with its multiple proprietary platform technology based on synthetic lethality, to develop broad-spectrum anti-cancer drugs and strives to become the pioneer in developing novel and next-generation cancer therapies.”
ACB will be presenting its innovative drug discovery platforms and pipeline at the LSX Inv€$tival Showcase in November.
-ENDS-
For further information, please contact:
At the company
Anticancer Bioscience:
bd@anticancerbio.com
Media Relations
Scius Communications
Sue Charles
+44 (0) 7968 726585
sue@sciuscommunications.com
About Anticancer Bioscience
Anticancer Bioscience (ACB) is an international private company, commercializing discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. With pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China. ACB is based on over 20 years of collaborative research between the founder Dr. Dun Yang and his Nobel laureate mentor Dr. J. Michael Bishop. It has raised CNY131M (around USD21M) and has around 50 employees in Chengdu, China, Hyderabad, India, Sydney, Australia, St Andrews, UK, and San Francisco, USA.
